Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
ACTIVE_NOT_RECRUITING
Status
Conditions
- Constitutional Mismatch Repair Deficiency Syndrome
- Lynch Syndrome
- Malignant Glioma
- Recurrent Brain Neoplasm
- Recurrent Childhood Ependymoma
- Recurrent Diffuse Intrinsic Pontine Glioma
- Recurrent Medulloblastoma
- Refractory Brain Neoplasm
- Refractory Diffuse Intrinsic Pontine Glioma
- Refractory Ependymoma
- Refractory Medulloblastoma
Interventions
- PROCEDURE: Biospecimen Collection
- PROCEDURE: Conventional Magnetic Resonance Imaging
- PROCEDURE: Diffusion Tensor Imaging
- PROCEDURE: Diffusion Weighted Imaging
- PROCEDURE: Dynamic Contrast-enhanced MR Perfusion
- PROCEDURE: Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging
- PROCEDURE: Magnetic Resonance Spectroscopic Imaging
- BIOLOGICAL: Pembrolizumab
Sponsor
National Cancer Institute (NCI)